Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea
The most prescribed antidiabetic drugs in Indonesian primary health care are metformin or a combination of metformin and sulfonylurea. Studies on metformin have shown various impacts on cognitive decline in patients with type 2 diabetes mellitus, whereas sulfonylurea has been shown to reduce this im...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Indonesia
2022-11-01
|
| Series: | Kesmas: Jurnal Kesehatan Masyarakat Nasional |
| Subjects: | |
| Online Access: | https://journal.fkm.ui.ac.id/kesmas/article/view/6303 |
| _version_ | 1797696092875259904 |
|---|---|
| author | Abu Rachman Rani Sauriasari Nadia Farhanah Syafhan Pukovisa Prawiroharjo Hindun Wilda Risni |
| author_facet | Abu Rachman Rani Sauriasari Nadia Farhanah Syafhan Pukovisa Prawiroharjo Hindun Wilda Risni |
| author_sort | Abu Rachman |
| collection | DOAJ |
| description | The most prescribed antidiabetic drugs in Indonesian primary health care are metformin or a combination of metformin and sulfonylurea. Studies on metformin have shown various impacts on cognitive decline in patients with type 2 diabetes mellitus, whereas sulfonylurea has been shown to reduce this impact. This study aimed to compare the impacts of metformin and metformin-sulfonylurea on cognitive function and determine what factors affected it. This cross-sectional study was conducted at Pasar Minggu Primary Health Care involving 142 type 2 diabetes mellitus patients taking metformin or metformin-sulfonylurea for > 6 months and aged > 36 years. Cognitive function was assessed using the validated Montreal Cognitive Assessment Indonesian version. The effects of metformin and metformin-sulfonylurea on cognitive decline showed no significant difference, even after controlling for covariates (aOR = 1.096; 95% CI = 0.523–2.297; p-value = 0.808). Multivariate analysis showed age (OR = 4.131; 95% CI = 1.271–13.428; p-value = 0.018) and education (OR = 2.746; 95% CI = 1.196–6.305; p-value = 0.017) affected cognitive function. Since a lower education and older age are likely to cause cognitive decline, health professionals are encouraged to work with public health experts to address these risk factors for cognitive function. |
| first_indexed | 2024-03-12T03:21:36Z |
| format | Article |
| id | doaj.art-f1c32f7c4df6442bba484d508c0492f4 |
| institution | Directory Open Access Journal |
| issn | 1907-7505 2460-0601 |
| language | English |
| last_indexed | 2024-03-12T03:21:36Z |
| publishDate | 2022-11-01 |
| publisher | Universitas Indonesia |
| record_format | Article |
| series | Kesmas: Jurnal Kesehatan Masyarakat Nasional |
| spelling | doaj.art-f1c32f7c4df6442bba484d508c0492f42023-09-03T13:57:45ZengUniversitas IndonesiaKesmas: Jurnal Kesehatan Masyarakat Nasional1907-75052460-06012022-11-0117427027810.21109/kesmas.v17i4.63031416Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-SulfonylureaAbu Rachman0Rani Sauriasari1Nadia Farhanah Syafhan2Pukovisa Prawiroharjo3Hindun Wilda Risni4Faculty of Pharmacy Universitas IndonesiaFaculty of Pharmacy Universitas IndonesiaFaculty of Pharmacy Universitas IndonesiaDepartment of Neurology, Faculty of Medicine Universitas IndonesiaFaculty of Pharmacy Universitas IndonesiaThe most prescribed antidiabetic drugs in Indonesian primary health care are metformin or a combination of metformin and sulfonylurea. Studies on metformin have shown various impacts on cognitive decline in patients with type 2 diabetes mellitus, whereas sulfonylurea has been shown to reduce this impact. This study aimed to compare the impacts of metformin and metformin-sulfonylurea on cognitive function and determine what factors affected it. This cross-sectional study was conducted at Pasar Minggu Primary Health Care involving 142 type 2 diabetes mellitus patients taking metformin or metformin-sulfonylurea for > 6 months and aged > 36 years. Cognitive function was assessed using the validated Montreal Cognitive Assessment Indonesian version. The effects of metformin and metformin-sulfonylurea on cognitive decline showed no significant difference, even after controlling for covariates (aOR = 1.096; 95% CI = 0.523–2.297; p-value = 0.808). Multivariate analysis showed age (OR = 4.131; 95% CI = 1.271–13.428; p-value = 0.018) and education (OR = 2.746; 95% CI = 1.196–6.305; p-value = 0.017) affected cognitive function. Since a lower education and older age are likely to cause cognitive decline, health professionals are encouraged to work with public health experts to address these risk factors for cognitive function.https://journal.fkm.ui.ac.id/kesmas/article/view/6303cognitive declinecognitive functiondiabetes mellitusmetforminmetformin-sulfonylurea |
| spellingShingle | Abu Rachman Rani Sauriasari Nadia Farhanah Syafhan Pukovisa Prawiroharjo Hindun Wilda Risni Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea Kesmas: Jurnal Kesehatan Masyarakat Nasional cognitive decline cognitive function diabetes mellitus metformin metformin-sulfonylurea |
| title | Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea |
| title_full | Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea |
| title_fullStr | Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea |
| title_full_unstemmed | Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea |
| title_short | Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea |
| title_sort | cognitive function in type 2 diabetes mellitus patients taking metformin and metformin sulfonylurea |
| topic | cognitive decline cognitive function diabetes mellitus metformin metformin-sulfonylurea |
| url | https://journal.fkm.ui.ac.id/kesmas/article/view/6303 |
| work_keys_str_mv | AT aburachman cognitivefunctionintype2diabetesmellituspatientstakingmetforminandmetforminsulfonylurea AT ranisauriasari cognitivefunctionintype2diabetesmellituspatientstakingmetforminandmetforminsulfonylurea AT nadiafarhanahsyafhan cognitivefunctionintype2diabetesmellituspatientstakingmetforminandmetforminsulfonylurea AT pukovisaprawiroharjo cognitivefunctionintype2diabetesmellituspatientstakingmetforminandmetforminsulfonylurea AT hindunwildarisni cognitivefunctionintype2diabetesmellituspatientstakingmetforminandmetforminsulfonylurea |